Earnings ·
Purple Biotech Ltd. reported second quarter 2026 financial results on August 7, 2026
PPBTPurple Biotech Ltd.
Purple Biotech Ltd. reported second quarter 2026 financial results on August 7, 2026. The company held $6.1 million in cash as of June 30, 2026, providing a runway through mid-2027. R&D expenses rose to $0.7 million from $0.6 million year-over-year, while G&A decreased to $0.6 million from $0.7 million. Operating loss was $1.3 million compared to $1.2 million in the prior period. Net income turned positive at $0.4 million due to a non-cash gain from warrant revaluation, contrasting with a net loss of $1.1 million previously. The company presented new preclinical data for IM1240 at EACR 2026 and plans to enter clinical studies in 2027. Purple Biotech Ltd. is a clinical-stage biotechnology company developing next-generation immunotherapy platforms.